Oneness Biotech Co., Ltd.

Oneness Biotech has licensed out OB318, a novel drug candidate for hepatocellular carcinoma to Microbio Shanghai for co-development and commercialization in mainland China, Hong Kong and Macao.

2017-11-10

Oneness Biotech has signed an exclusive licensing agreement with Microbio Shanghai for the development of OB318. Under the agreement, Microbio Shanghai will cover the development and commercialization of OB318 in mainland China, Hong Kong and Macao. The license payment will be converted into investment in company shares of MicroBio Shanghai.